A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies

Table 1

Patients’ characteristics (N = 25).

	N = 25
Age, median (range)	57 (35, 68)
Male sex	11 (44%)
Diagnosis
AML	11 (44%)
ALL	4 (16%)
MDS/MPS	6 (24%)
NHL/CLL	3 (12%)
PCD	1 (4%)
Patient CMV
Positive	18 (72%)
Negative	7 (28%)
ABO compatibility
Compatible	16 (64%)
Incompatible minor	2 (8%)
Incompatible minor and major	1 (4%)
Incompatible major	6 (24%)
DRI
Low	1 (4%)
Intermediate	13 (76%)
High/very high	11 (16%)
CMl
1–3	11 (44%)
4–8	14 (56%)
Female donor male recipient	4 (16%)
Year of transplantation
2015	3 (12%)
2016	8 (32%)
2017	6 (24%)
2018	8 (32%)
Number of survivors	14
Survivor follow-up (month), median (range)	28.3 (8.7, 43.9)